Clinical trials: Chronic Infection
HIV Infections
Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients
The purpose of this study is to examine the safety, tolerability, and immune response to killed-whole HIV-1 (SAV001-H) vaccine as a primary vaccination regimen in HIV infected individuals.
- Trial name
- NCT01546818
- Testing
- SAV001-H
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sumagen
Hepatitis C, Chronic
Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)
The current gold standard for treatment of chronic hepatitis C (CHC) patients is with pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness.
- Trial name
- SATISFACTION (NCT00727259)
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
- Volunteers
- 1,995 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy
This study is being conducted to compare the safety, effectiveness and tolerance of valopicitabine (NM283) when used alone and when valopicitabine is used together with pegylated interferon in hepatitis C treatment failure…
- Trial name
- NCT00120861
- Testing
- valopicitabine, pegylated interferon, ribavirin
- Where
- 11 sites in United States
- Sponsor
- Merck Sharp & Dohme LLC
Acute Bronchitis, Chronic Bronchitis
Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis
The study will conduct with 4 comparative groups orally treated with YHD001 dose level 1(t.i.d.), YHD001 dose level 2(t.i.d.), pelargonium sidoides extract 9mL(t.i.d.) or Placebo for 7 days.
- Trial name
- NCT01420445
- Testing
- YHD001 dose level 1, YHD001 dose level 2, Pelargonium sidoides extract
- Where
- South Korea
- Volunteers
- 118 people
- Sponsor
- Yuhan Corporation
Pseudomonas Aeruginosa in Cystic Fibrosis
Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
This is a multicenter, prospective, two cohort, observational study over a 5-year period in Cystic Fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection.The study will collect data over 1 year on respiratory…
- Trial name
- NCT02449031
- Testing
- TOBI® PODHALER®, TOBI®, Bethkis®
- Where
- 47 sites in United States
- Volunteers
- 409 people
- Sponsor
- Mylan Inc.
Hepatitis, Hepatitis C
An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic hepatitis C in Human Immunodeficiency Virus-1…
- Conditions
- Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection
- Trial name
- NCT02103439
- Testing
- Algeron, PegIntron
- Where
- 6 sites in Russia
- Volunteers
- 140 people
- Sponsor
- Biocad
Hepatitis C, Chronic
A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)
This study will compare the efficacy and safety of 2 different treatment durations of peginterferon alfa-2a (Pegasys) plus ribavirin in patients with CHC.
- Trial name
- NCT02641379
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 21 sites in Austria
- Volunteers
- 737 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B
This study is a Multiple Ascending Dose study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of APG-1387 in Chronic Hepatitis B Patients.
- Trial name
- NCT03585322
- Testing
- APG-1387 for Injection
- Where
- 2 sites in China
- Volunteers
- 49 people
- Sponsor
- Ascentage Pharma Group Inc.
Hepatitis C, Chronic, Hepatitis C
Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671)
Enrolled patients will be recruited to two parallel groups during therapy for Hepatitis C. Patients in the first one will receive a patient assistance program, and patients in the second group will not.
- Trial name
- NCT00728494
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908), Patient Assistance Program
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- 3DUTCH (NCT02817594)
- Where
- 9 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- AbbVie
Hepatitis B, Chronic
A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed
The purpose of this study is to evaluate the safety, tolerability, and reactogenicity of escalating doses of JNJ-64300535 delivered via electroporation-mediated intramuscular injection in nucleos(t)ide analogs (NA)-treated…
- Trial name
- NCT03463369
- Testing
- JNJ-64300535, Nucleos(t)ide Analogs (NA)
- Where
- 14 sites in Belgium, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Janssen Sciences Ireland UC
Hepatitis C, Chronic
A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of setrobuvir in patients with genotype 1 chronic hepatitis C.
- Trial name
- NCT01903954
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus], setrobuvir
- Volunteers
- 283 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Infection
Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults
The study will evaluate the safety and pharmacokinetics of single doses of VBY-376 in healthy subjects.
- Trial name
- NCT00557583
- Testing
- VBY 376
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Virobay Inc.
Chronic Hepatitis C
Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital
This study presents a clinical study on the efficacy and safety of Pegnano combined with Barivir (Ribavirin) in treating treatment-naïve patients with Chronic Hepatitis C at Kien Giang General Hospital.
- Trial name
- NCT06922643
- Testing
- Peginterferon Alfa-2A, Ribavirin Oral Product
- Volunteers
- 100 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Hepatitis C, HCV
TD-6450 MAD Study in HCV Infected Subjects
This proof of concept study is designed to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of TD-6450 in treatment naïve subjects with GT-1, GT-2 or GT-3 chronic HCV.
- Trial name
- NCT02116543
- Testing
- TD-6450
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Theravance Biopharma
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Trial name
- NCT00064415
- Testing
- arformoterol, Salmeterol
- Where
- 90 sites in United States
- Volunteers
- 799 people
- Sponsor
- Sumitomo Pharma America, Inc.
Hepatitis C, Chronic
Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)
This study involves treatment with boceprevir or placebo in combination with PegIntron (PEG) + Ribavirin (RBV) (weight-based dosing [WBD]) in previously untreated adult participants with chronic hepatitis C (CHC) genotype 1.
- Trial name
- SPRINT-2 (NCT00705432)
- Testing
- Peginterferon alfa-2b (PEG), Ribavirin (RBV), Boceprevir
- Volunteers
- 1,472 people
- Sponsor
- Merck Sharp & Dohme LLC
Keratitis, Corneal Ulcer
Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
The purpose of this study is to assess the efficacy and safety of T4020 versus vehicle.
- Trial name
- NCT01794312
- Testing
- T4020, Vehicle
- Where
- France
- Volunteers
- 152 people
- Sponsor
- Laboratoires Thea
Chronic Hepatitis B
A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors
This is a multicenter, randomized, controlled Phase IIa study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus.
- Trial name
- NCT05839639
- Testing
- NrtIs, HH-003, HH-003+NrtIs
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Huahui Health
Hepatitis C
Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
To study the combination of Daclatasvir and Sofosbuvir for the treatment of hepatitis C virus (HCV) Genotype 3 infection
- Trial name
- ALLY 3 (NCT02032901)
- Testing
- Daclatasvir, Sofosbuvir
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 173 people
- Sponsor
- Bristol-Myers Squibb